Status:
NOT_YET_RECRUITING
Creatine and Resistance Training in Older Adults With Mild Cognitive Impairment
Lead Sponsor:
Western University, Canada
Collaborating Sponsors:
Alzheimer Society of Canada
Conditions:
Creatine
Exercise
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
The goal of this 26-week trial is to learn if creatine supplementation and resistance training (i.e., weightlifting; exercise that increases muscle mass), alone and together, impact cognition, brain h...
Detailed Description
Research objectives: To evaluate the effects of 26 weeks of creatine supplementation on its own and in combination with progressive resistance training in community-dwelling older adults with mild co...
Eligibility Criteria
Inclusion
- To be eligible to participate in this study participants must:
- be 60 years of age or older,
- live independently in the community,
- have normal or corrected-to-normal vision and hearing,
- read, write, and speak English fluently,
- be right-handed,
- have subjective feelings of memory decline in the past 5 years,
- have MoCA scores 19-25/30 (assessed at baseline session),
- be able to exercise at a moderate pace using resistance training for 60 minutes 3x/week,
- receive clearance from a physician to participate in an exercise program, and 10) receive confirmation from a physician that they meet all criteria to be included in this study.
- Participants are ineligible if they:
- cannot partake or commit to exercise training 3x/week for 26 weeks or have regularly (\>1x/week) engaged in exercise training over the past 3 months;
- cannot partake or commit to consuming a daily supplement for 26 weeks or consumed nutritional supplements containing creatine monohydrate over the past 3 months;
- have a known allergy to creatine monohydrate or dextrose;
- have been diagnosed with a neurological disorder (e.g., Alzheimer's disease, Parkinson's disease);
- have pre-existing kidney disease, heart disease, or liver abnormalities;
- have one or more uncontrolled chronic or psychiatric conditions (e.g., hypertension, diabetes, depression, anxiety);
- are taking medication that may impact kidney function (e.g., non-steroidal anti-inflammatory drugs, such as ibuprofen and naproxen); or
- are ineligible or uncomfortable with MRI (have metal or electronic implants, claustrophobia) or blood sampling.
Exclusion
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06948149
Start Date
September 1 2025
End Date
December 1 2027
Last Update
August 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Western University
London, Ontario, Canada, N6E 1Z6